Tetrathiomolybdate protects against bile duct ligation-induced cholestatic liver injury and fibrosis

Journal of Pharmacology and Experimental Therapeutics

Volumn 325, Issue 2, 2008, Pages 409-416

  Song, Ming ^a   Song, Zhenyuan ^a   Barve, Shirish ^a   Zhang, Jingwen ^a   Chen, Theresa ^a   Liu, Marcia ^a   Arteel, Gavin E ^a   Brewer, George J ^c   McClain, Craig J ^a,b  

^a University of Louisville School of Medicine   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYALKENAL DERIVATIVE; ALKENE DERIVATIVE; ALPHA SMOOTH MUSCLE ACTIN; BILIRUBIN; COPPER; GLUTATHIONE; LIVER ENZYME; MALONALDEHYDE; TETRATHIOMOLYBDIC ACID; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CERULOPLASMIN; GAMMA GLUTAMYLTRANSFERASE; MOLYBDENUM; PROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT LIGATION; BILIARY EXCRETION; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; GENE EXPRESSION; HISTOPATHOLOGY; LIVER FIBROSIS; LIVER INJURY; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; ANIMAL; BILE DUCT; BLOOD; C57BL MOUSE; CHOLESTASIS; DISEASE MODEL; FIBROSIS; LIGATION; LIVER; METABOLISM; PATHOLOGY;

ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; BILE DUCTS; BILIRUBIN; CERULOPLASMIN; CHOLESTASIS; COPPER; DISEASE MODELS, ANIMAL; FIBROSIS; GAMMA-GLUTAMYLTRANSFERASE; GENE EXPRESSION; LIGATION; LIVER; MALE; MICE; MICE, INBRED C57BL; MOLYBDENUM; PROTECTIVE AGENTS; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 42449134964     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.131227     Document Type: Article

References (39)

1. Askari FK, Dick R, Mao M, and Brewer GJ (2004) Tetrathiomolybdate therapy protects against concanavalin A and carbon tetrachloride hepatic damage in mice. Exp Biol Med 229:857-863.
2. Barón V and Muriel P (1999) Role of glutathione, lipid peroxidation and antioxidants on acute bile-duct obstruction in the rat. Biochim Biophys Acta 1472:173-180.
3. Bergheim I, Guo L, Davis MA, Duveau I, and Arteel GE (2006) Critical role of plasminogen activator inhibitor-1 in cholestatic liver injury and fibrosis. J Pharmacol Exp Ther 316:592-600.
4. Brewer GJ, Dick RD, Grover DK, LeClaire V, Tseng M, Wicha M, Pienta K, Redman BG, Jahan T, Sondak VK, et al. (2000) Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: phase I study. Clin Cancer Res 6:1-10.
5. Brewer GJ, Dick R, Ullenbruch MR, Jin H, and Phan SH (2004) Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis. J Inorg Biochem 98:2160-2167.
6. Brewer GJ, Dick RD, Yuzbasiyan-Gurkin V, Tankanow R, Young AB, and Kluin KJ (1991) Initial therapy of patients with Wilson's disease with tetrathiomolybdate. Arch Neurol 48:42-47.
7. Brewer GJ, Dick R, Zeng C, and Hou G (2006) The use of tetrathiomolybdate in treating fibrotic, inflammatory, and autoimmune diseases, including the non-obese diabetic mouse model. J Inorg Biochem 100:927-930.
8. Brewer GJ, Ullenbruch MR, Dick R, Olivarez L, and Phan SH (2003) Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice. J Lab Clin Med 141:210-216.
9. Cox C, Merajver SD, Yoo S, Dick RD, Brewer GJ, Lee JS, and Teknos TN (2003) Inhibition of the growth of squamous cell carcinoma by tetrathiomolybdate-induced copper suppression in a murine model. Arch Otolaryngol Head Neck Surg 129:781-785.
10. Deering TB, Dickson ER, Fleming CR, Geall MG, McCall JT, and Baggenstoss AH (1977) Effect of D-penicillamine on copper retention in patients with primary biliary cirrhosis. Gastroenterology 72:1208-1212.
11. Ebara M, Fukuda H, Hatano R, Yoshikawa M, Sugiura N, Saisho H, Kondo F, and Yukawa M (2003) Metal contents in the liver of patients with chronic liver disease caused by hepatitis C virus. Reference to hepatocellular carcinoma. Oncology 65:323-330.
12. Elner SG, Elner VM, Yoshida A, Dick RD, and Brewer GJ (2005) Effects of tetrathiomolybdate in a mouse model of retinal neovascularization. Invest Ophthalmol Vis Sci 46:299-303.
13. Esterbauer H, Schaur RJ, and Zollner H (1991) Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11:81-128.
14. Goodman VL, Brewer GJ, and Merajver SD (2004) Copper deficiency as an anticancer strategy. Endocr Relat Cancer 11:255-263.
15. Hou G, Dick R, Abrams GD, and Brewer GJ (2005) Tetrathiomolybdate protects against cardiac damage by doxorubicin in mice. J Lab Clin Med 146:299-303.
16. Jiang Y, Reynolds C, Xiao C, Feng W, Zhou Z, Rodriguez W, Tyagi SC, Eaton JW, Saari JT, and Kang YJ (2007) Dietary copper supplementation reverses hypertrophic cardiomyopathy induced by chronic pressure overload in mice. J Exp Med 204:657-666.
17. Kawamura K, Kobayashi Y, Kageyama F, Kawasaki T, Nagasawa M, Toyokuni S, Uchida K, and Nakamura H (2000) Enhanced hepatic lipid peroxidation in patients with primary biliary cirrhosis. Am J Gastroenterol 95:3596-3601.
18. Linder MC and Hazegh-Azam M (1996) Copper biochemistry and molecular biology. Am J Clin Nutr 63:797S-811S.
19. -ΔΔCt method. Methods 25:402-408.
20. López-De León A and Rojkind M (1985) A simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded sections. J Histochem Cytochem 33:737-743.
21. Lowndes SA and Harris AL (2005) The role of copper in tumour angiogenesis. J Mammary Gland Biol Neoplasia 10:299-310.
22. Luza SC and Speisky HC (1996) Liver copper storage and transport during development: implications for cytotoxicity. Am J Clin Nutr 63:812S-820S.
23. Ma S, Hou G, Dick RD, and Brewer GJ (2004) Tetrathiomolybdate protects against liver injury from acetaminophen in mice. J Appl Res Clin Exp Ther 4:419-426.
24. Martin F, Linden T, Katschinski DM, Oehme F, Flamme I, Mukhopadhyay CK, Eckhardt K, Troger J, Barth S, Camenisch G, et al. (2005) Copper-dependent activation of hypoxia-inducible factor (HIF)-1: implications for ceruloplasmin regulation. Blood 105:4613-4619.
25. McCubbin MD, Hou G, Abrams GD, Dick R, Zhang Z, and Brewer GJ (2006) Tetrathiomolybdate is effective in a mouse model of arthritis. J Rheumatol 33:2501-2506.
26. Mills CF, El-Gallad TT, Bremner I, and Weham G (1981) Copper and molybdenum absorption by rats given ammonium tetrathiomolybdate. J Inorg Biochem 14:163-175.
27. Murata Y, Yamakawa E, Iizuka T, Kodama H, Abe T, Seki Y, and Kodama M (1995) Failure of copper incorporation into ceruloplasmin in the Golgi apparatus of LEC rat hepatocytes. Biochem Biophys Res Commun 209:349-355.
28. Omoto A, Kawahito Y, Prudovsky I, Tubouchi Y, Kimura M, Ishino H, Wada M, Yoshida M, Kohno M, Yoshimura R, et al. (2005) Copper chelation with tetrathiomolybdate suppresses adjuvant-induced arthritis and inflammation-associated cachexia in rats. Arthritis Res Ther 7:R1174-R1182.
29. Pan Q, Kleer CG, van Golen KL, Irani J, Bottema KM, Bias C, De Carvalho M, Mesri EA, Robins DM, Dick RD, et al. (2002) Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res 62:4854-4859.
30. Richie JP Jr and Lang CA (1987) The determination of glutathione, cyst(e)ine, and other thiols and disulfides in biological samples using high-performance liquid chromatography with dual electrochemical detection. Anal Biochem 163:9-15.
31. Roderfeld M, Weiskirchen R, Wagner S, Berres ML, Henkel C, Grotzinger J, Gressner AM, Matern S, and Roeb E (2006) Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice. FASEB J 20:444-454.
32. Schosinsky KH, Lehmann HP, and Beeler MF (1974) Measurement of ceruloplasmin from its oxidase activity in serum by use of o-dianisidine dihydrochloride. Clin Chem 20:1556-1563.
33. Shi YF, Fong CC, Zhang Q, Cheung PY, Tzang CH, Wu RS, and Yang M (2007) Hypoxia induces the activation of human hepatic stellate cells LX-2 through TGF-beta signaling pathway. FEBS Lett 581:203-210.
34. Tahan G, Tarcin O, Tahan V, Eren F, Gedik N, Sahan E, Biberoglu N, Guzel S, Bozbas A, Tozun N, et al. (2007) The effects of N-acetylcysteine on bile duct ligation-induced liver fibrosis in rats. Dig Dis Sci 52:3348-3354.
35. Togashi Y, Li Y, Kang JH, Takeichi N, Fujioka Y, Nagashima K, and Kobayashi H (1992) D-Penicillamine prevents the development of hepatitis in Long-Evans Cinnamon rats with abnormal copper metabolism. Hepatology 15:82-87.
36. Uchinami H, Seki E, Brenner DA, and D'Armiento J (2006) Loss of MMP 13 attenuates murine hepatic injury and fibrosis during cholestasis. Hepatology 44:420-429.
37. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H, Yanase K, Namisaki T, Imazu H, et al. (2002) Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. Hepatology 36:850-860.
38. Zelko IN, Mariani TJ, and Folz RJ (2002) Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. Free Radic Biol Med 33:337-349.
39. Zhong Z, Froh M, Wheeler MD, Smutney O, Lehmann TG, and Thurman RG (2002) Viral gene delivery of superoxide dismutase attenuates experimental cholestasis-induced liver fibrosis in the rat. Gene Ther 9:183-191.